Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Government Contract opportunity from Department Of Defense was posted on November 10, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Human Blood for Research Utilizing Malaria Parasite Cultures

Closed
FY25-0423Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414
Federal
Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC)
Solicitation # 12639527R0001
Solicitation 12639527R0001 is a request for proposals issued by the USDA Animal and Plant Health Inspection Service (APHIS) for an Indefinite Delivery Indefinite Quantity (IDIQ) contract. The requirement covers the purchase, storage, and production of Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC), the conversion of Government-owned VAC into usable finished vaccines, and the direct purchase of finished vaccines. The contract has a ceiling price of 800 million dollars and a long-term performance horizon, featuring five one-year ordering periods starting approximately December 1, 2026, with conversion and delivery of finished vaccines extending through November 30, 2044. The scope of work requires the contractor to produce VAC capable of yielding at least 1.0 million doses and maintain these materials on their premises under strict quality control and temperature standards. Because live FMDV is a Tier 1 Select Agent, the contractor must hold a select agent authorization issued by CDC/APHIS. Finished vaccines must be packaged to maintain temperatures between 2 to 8 degrees Celsius for 24 hours and include electronic temperature monitors. Award will be based on the most advantageous offer considering technical capability, past performance from the last five years, and fair and reasonable pricing. Proposals must be submitted electronically to Stephen Tees by November 10, 2026, at 1700 CT, organized into four separate volumes.
Mrpbs Minneapolis Mn

POSTED

19 days ago

DEADLINE

in 21 days

General Info

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Place of Performance

Silver Spring, MD, USA

Set-Aside

NONE

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

special-notice

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Army Medical Resources Acq Activity
Contacts1 person available
OfficeFORT DETRICK, MD, 21702, USA
Office AddressFORT DETRICK, MD, 21702, USA

Full Description

Show more

The Defense Health Agency Contracting Activity (DHACA) – R&D Branch 1 intends to negotiate on a sole source basis, IAW 41 United Stated Code 1901 as implemented in FAR 13.501 to ZenBio Inc., 3920 Sount Alston Ave, Durham NC 27713, as the only responsible source that can provide the Walter Reed Army Institute of Research (WRAIR), with regular, scheduled, supply deliveries of screened human blood products that meet the Governments requirements  in support of malaria vaccine research.  All human blood products provided will have been tested in accordance with 21 Code of Federal Regulations (CFR) Part 310.40 General Biological Products Standards Testing Requirements for Relevant Transfusion-Transmitted Infections and each unit of blood/serum will be FDA certified and accompanied with a Certificate of Analysis (CoA). The screened human blood products provided must be certified to have been tested, at a minimum, for Human Immunodeficiency virus, type 1, 2 (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human T-lymphotropic virus, type I,2 (HTLV), Syphilis (T. pallidum), Chagas (T. cruzi), West Nile virus and Zika virus, in order to meet malaria research requirements.


   


 



Not proprietary.    

More opportunities from Department Of Defense → Army Medical Resources Acq Activity

Same awarding agency

NAICS: 813920
New
Federal
Biomedical Research Application Evaluation and Support (BRAES)
Solicitation # HT942727RE006
The Biomedical Research Application Evaluation and Support (BRAES) contract is a performance-based, non-commercial Multiple Award Indefinite Delivery Indefinite Quantity (MA-IDIQ) solicitation issued by the Defense Health Agency for the Congressionally Directed Medical Research Programs. With a ceiling cost of 137 million dollars and an estimated period of performance from January 2027 to January 2032, the contract supports the evaluation of biomedical research applications. The scope is divided into four primary areas: funding opportunity announcement set-up, oversight of application receipt and processing, application compliance review, and scientific merit peer review. While the first three tasks are awarded to a single vendor via the eBRAP task order, the scientific peer review tasks are awarded to multiple vendors through Science Administration and Management (SAM) task orders, which require the operation of a secure, contractor-owned, contractor-operated (COCO) web-based system. The government will utilize a Highest Technically Rated with a Fair and Reasonable Cost/Price approach to select approximately three awardees. Evaluation factors include technical approach, management approach, past performance, and small business participation, with cost and price serving as the final check for the highest-rated proposals. Key requirements for offerors include an active SAM registration, a CMMC Level 1 self-assessment, and the submission of a five-volume proposal by December 2, 2026. Contract administration involves a mix of Cost Plus Fixed Fee and Firm Fixed Price arrangements, with invoicing processed through the Wide Area Workflow system. Performance is monitored via Quality Assurance Surveillance Plans using random sampling and 100 percent inspection to determine CPARS ratings based on accuracy and schedule adherence.
Professional Organizations

POSTED

1 day ago

DEADLINE

in about 1 month
View Details
NAICS: 541715
New
Federal
Mild Traumatic Brain Injury (mTBI) Blast Injury Prevention Standards Request for Information
Solicitation # CB4_SW_mTBI_RFI
The Army Medical Resources Acq Activity, specifically the USAMRDC and the Department of War Blast Injury Research Coordinating Office in collaboration with The MITRE Corporation, has issued a Request for Information regarding Mild Traumatic Brain Injury blast injury prevention standards. This initiative aims to identify existing and emerging injury criteria, thresholds, standards, and models to inform the Military Health System Blast Injury Prevention Standards Recommendation process. The primary goal is to gather biomedically valid data, such as dose response curves and injury thresholds, to improve health hazard assessments, survivability assessments, and the development of protection systems for service members exposed to explosive weapons. This notice is issued solely for information and program planning purposes and does not constitute a formal solicitation for proposals. In accordance with FAR 15.201(e), responses are not considered offers and cannot be accepted to form a binding contract, nor will the government provide reimbursement for costs associated with participating. Interested parties from industry, academia, and other federal agencies are encouraged to submit relevant publications, reports, and images through a specific online submission process. The primary point of contact for this effort is Contract Specialist Skylar Wells, and the response deadline is November 3, 2026.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

4 days ago

DEADLINE

in 14 days
View Details

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS